WO2006012642A3 - Pyrrole derivatives as pharmaceutical agents - Google Patents
Pyrrole derivatives as pharmaceutical agents Download PDFInfo
- Publication number
- WO2006012642A3 WO2006012642A3 PCT/US2005/026916 US2005026916W WO2006012642A3 WO 2006012642 A3 WO2006012642 A3 WO 2006012642A3 US 2005026916 W US2005026916 W US 2005026916W WO 2006012642 A3 WO2006012642 A3 WO 2006012642A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical agents
- pyrrole derivatives
- receptors
- activity
- modulating
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 150000003233 pyrroles Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000000051 modifying Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59243904P true | 2004-07-30 | 2004-07-30 | |
US59246904P true | 2004-07-30 | 2004-07-30 | |
US60/592,439 | 2004-07-30 | ||
US60/592,469 | 2004-07-30 |
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK05803281.4T DK1773768T3 (en) | 2004-07-30 | 2005-07-30 | PYRROLD DERIVATIVES AS PHARMACEUTICAL AGENTS |
CA2573426A CA2573426C (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
KR1020077004302A KR101155288B1 (en) | 2004-07-30 | 2005-07-30 | Pyrrole Derivatives as Pharmaceutical Agents |
ES05803281T ES2697524T3 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
JP2007523832A JP4703649B2 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
RU2007107388/04A RU2470916C2 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as medicinal substances |
CN200580026842.3A CN101006052B (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
NZ552632A NZ552632A (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
BRPI0513677A BRPI0513677B8 (en) | 2004-07-30 | 2005-07-30 | pyrrole derivatives as pharmaceutical agents |
LTEP05803281.4T LT1773768T (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
EP05803281.4A EP1773768B8 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
AU2005266890A AU2005266890C1 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
US11/572,962 US8026237B2 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
PL05803281T PL1773768T3 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
SI200532237T SI1773768T1 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
IL180630A IL180630A (en) | 2004-07-30 | 2007-01-10 | Pyrrole derivatives as pharmaceutical agents |
NO20070910A NO344324B1 (en) | 2004-07-30 | 2007-02-16 | Pyrrole derivatives as pharmaceuticals |
US13/214,665 US8367667B2 (en) | 2004-07-30 | 2011-08-22 | Pyrrole derivatives as pharmaceutical agents |
CY181101235T CY1120922T1 (en) | 2004-07-30 | 2018-11-21 | PYRROL PRODUCTS AS PHARMACEUTICAL AGENTS |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/572,962 A-371-Of-International US8026237B2 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
US13/214,665 Division US8367667B2 (en) | 2004-07-30 | 2011-08-22 | Pyrrole derivatives as pharmaceutical agents |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006012642A2 WO2006012642A2 (en) | 2006-02-02 |
WO2006012642A3 true WO2006012642A3 (en) | 2006-07-27 |
Family
ID=35786783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/026916 WO2006012642A2 (en) | 2004-07-30 | 2005-07-30 | Pyrrole derivatives as pharmaceutical agents |
Country Status (21)
Country | Link |
---|---|
US (2) | US8026237B2 (en) |
EP (1) | EP1773768B8 (en) |
JP (2) | JP4703649B2 (en) |
KR (1) | KR101155288B1 (en) |
AU (1) | AU2005266890C1 (en) |
BR (1) | BRPI0513677B8 (en) |
CA (1) | CA2573426C (en) |
CY (1) | CY1120922T1 (en) |
DK (1) | DK1773768T3 (en) |
ES (1) | ES2697524T3 (en) |
HU (1) | HUE041596T2 (en) |
IL (1) | IL180630A (en) |
LT (1) | LT1773768T (en) |
NO (1) | NO344324B1 (en) |
NZ (1) | NZ552632A (en) |
PL (1) | PL1773768T3 (en) |
PT (1) | PT1773768T (en) |
RU (1) | RU2470916C2 (en) |
SG (1) | SG155188A1 (en) |
SI (1) | SI1773768T1 (en) |
WO (1) | WO2006012642A2 (en) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE027546T2 (en) | 2003-08-29 | 2016-10-28 | The Brigham And Women's Hospital Inc | Hydantoin derivatives as inhibitors of cellular necrosis |
SE0302573D0 (en) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
AT545644T (en) | 2004-09-24 | 2012-03-15 | Astrazeneca Ab | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND APPLICATIONS THEREOF |
DE10354060A1 (en) * | 2003-11-19 | 2005-06-02 | Merck Patent Gmbh | pyrrole |
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
JP4703649B2 (en) * | 2004-07-30 | 2011-06-15 | エグゼリクシス, インコーポレイテッド | Pyrrole derivatives as pharmaceutical agents |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
WO2006074244A2 (en) | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
KR101302627B1 (en) | 2005-01-05 | 2013-09-10 | 아비에 인코포레이티드 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US20110144128A1 (en) * | 2005-01-10 | 2011-06-16 | Exelixis, Inc. | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands |
TW200745049A (en) | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
AP2527A (en) | 2006-10-31 | 2012-12-06 | Pfizer Prod Inc | Pyrazoline compounds as mineralocorticoid receptorantagonists |
BRPI0809656B8 (en) * | 2007-04-09 | 2021-05-25 | Daiichi Sankyo Co Ltd | atropisomer, compound, prophylactic or therapeutic agent, and pharmaceutical composition |
WO2009023272A1 (en) * | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Heterocyclic inhibitors of necroptosis |
JP5736098B2 (en) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | Pharmaceutical composition for treating central nervous system disorders |
CA2696429A1 (en) * | 2007-08-22 | 2009-02-26 | Allergan, Inc. | Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity |
RU2465272C2 (en) | 2007-09-10 | 2012-10-27 | КалсиМедика, Инк. | Compounds modulating intracellular calcium |
US8389567B2 (en) * | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
PL2274303T3 (en) * | 2008-03-31 | 2013-03-29 | Teva Pharma | Processes for preparing sunitinib and salts thereof |
GB0808282D0 (en) * | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
CA2734154C (en) | 2008-08-15 | 2017-07-11 | N30 Pharmaceuticals, Llc | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
WO2010019905A1 (en) | 2008-08-15 | 2010-02-18 | N30 Pharmaceuticals, Llc | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
EP2315590B1 (en) | 2008-08-15 | 2012-09-26 | N30 Pharmaceuticals, LLC | Pyrrole inhibitors of s-nitrosoglutathione reductase |
WO2010027875A2 (en) * | 2008-08-27 | 2010-03-11 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
KR101643285B1 (en) * | 2008-10-08 | 2016-07-29 | 엑셀리시스, 인코포레이티드 | Atropisomers of (hydroxyalkyl)pyrrole derivatives |
CN102177137B (en) * | 2008-10-08 | 2015-03-18 | 埃克塞利希斯股份有限公司 | 1-phenylpyrrole compounds |
EP3000468A1 (en) | 2008-12-23 | 2016-03-30 | President and Fellows of Harvard College | Small molecule inhibitors of necroptosis |
WO2010107476A1 (en) * | 2009-03-19 | 2010-09-23 | Duke University | Inhibiting gsnor |
AU2010245072B2 (en) * | 2009-05-05 | 2013-11-28 | Merck Sharp & Dohme Corp. | p38 kinase inhibiting agents |
EP2253617A1 (en) * | 2009-05-20 | 2010-11-24 | Bayer CropScience AG | Halogenated compounds as pesticides |
WO2011025706A2 (en) | 2009-08-26 | 2011-03-03 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
WO2011034962A2 (en) * | 2009-09-16 | 2011-03-24 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
TWI532725B (en) * | 2010-01-26 | 2016-05-11 | 賽諾菲阿凡提斯公司 | Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
ES2566934T3 (en) | 2010-05-10 | 2016-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and / or under the retina |
US9241944B2 (en) | 2010-06-16 | 2016-01-26 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and compositions for stimulating reepithelialisation during wound healing |
JP5916149B2 (en) | 2010-08-27 | 2016-05-11 | カルシメディカ,インク. | Compounds that regulate intracellular calcium |
US20140113898A1 (en) * | 2010-11-08 | 2014-04-24 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
CA2856946C (en) | 2011-12-02 | 2016-08-02 | Phenex Pharmaceuticals Ag | Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmunediseases |
ES2797123T3 (en) | 2011-12-21 | 2020-12-01 | Novira Therapeutics Inc | Antiviral agents for hepatitis B |
EA027280B1 (en) | 2012-08-28 | 2017-07-31 | Янссен Сайенсиз Айрлэнд Юси | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
PL2961732T3 (en) | 2013-02-28 | 2017-09-29 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
WO2014145022A1 (en) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
AU2014247138B2 (en) | 2013-04-03 | 2018-06-28 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
KR20210018557A (en) | 2013-04-10 | 2021-02-17 | 다이이찌 산쿄 가부시키가이샤 | Crystal of pyrrole derivative and method for producing the same |
US10160743B2 (en) | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
EP3025711B1 (en) | 2013-07-23 | 2020-11-18 | Daiichi Sankyo Company, Limited | Medicine for preventing or treating hypertension |
JP6348978B2 (en) | 2013-07-25 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Glyoxamide-substituted pyrrolamide derivatives and their use as pharmaceuticals for treating hepatitis B |
HUE037007T2 (en) | 2013-08-27 | 2018-08-28 | Daiichi Sankyo Co Ltd | Method for producing pyrrole derivative, and intermediate thereof |
SG11201602748XA (en) | 2013-10-23 | 2016-05-30 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2015083130A1 (en) * | 2013-12-06 | 2015-06-11 | Aurigene Discovery Technologies Limited | Fused pyridine and pyrimidine derivatives as ror gamma modulators |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
CN106232136A (en) | 2014-02-05 | 2016-12-14 | 诺维拉治疗公司 | For treating the conjoint therapy of HBV infection |
UY35980A (en) | 2014-02-06 | 2015-08-31 | Janssen Sciences Ireland Uc | DERIVATIVES OF SULFAMOILPIRROLAMIDA AS INHIBITORS OF HBV AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
SG11201704764PA (en) | 2014-12-11 | 2017-07-28 | Harvard College | Inhibitors of cellular necrosis and related methods |
KR20170104486A (en) * | 2015-01-26 | 2017-09-15 | 다이이찌 산쿄 가부시키가이샤 | Solid composition of pyrrole carboxamide |
WO2016172496A1 (en) | 2015-04-23 | 2016-10-27 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
TWI623316B (en) * | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
WO2017151786A1 (en) | 2016-03-01 | 2017-09-08 | University Of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
KR20180123021A (en) | 2016-03-24 | 2018-11-14 | 다이이찌 산쿄 가부시키가이샤 | Medicines for the treatment of kidney disease |
WO2017181141A2 (en) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
CN109890379A (en) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | Combination product comprising sGC activator and mineralocorticoid receptor antagonists |
WO2018069126A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc stimulators and mineralocorticoid receptor antagonists |
CN109863137A (en) | 2016-10-26 | 2019-06-07 | 星座制药公司 | LSD1 inhibitor and its medical usage |
WO2018153898A1 (en) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selective partial adenosine a1 receptor agonists in combination with mineralocorticoid receptor antagonists |
DE102017008472A1 (en) | 2017-09-08 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Combination containing PDE5 inhibitors and mineralocorticoid receptor antagonists |
CN111867582A (en) | 2018-03-14 | 2020-10-30 | 爱尔兰詹森科学公司 | Capsid assembly modulator dosing regimen |
KR20210130753A (en) | 2019-02-22 | 2021-11-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Amide derivatives useful for the treatment of HBV infection or HBV-induced disease |
WO2021078135A1 (en) | 2019-10-25 | 2021-04-29 | 广东东阳光药业有限公司 | Pyrrole amide compound and use thereof |
RU2738405C1 (en) * | 2020-05-26 | 2020-12-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | Amide (e)-2-amino-4-oxo-5-(2-oxo-2-phenylethylidene)-1-(3-ethoxycarbonyl)-4,5,6-7-tetrahydrobenzo[b]thiophen-2-yl)4,5-dihydro-1h-pyrrole-3-carboxylic acid, having antimicrobial activity |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058249A1 (en) * | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators |
US20040267028A1 (en) * | 2001-09-24 | 2004-12-30 | Smith Roger A | Preparation and use of pyrrole derivatives for treating obesity |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR8008732A (en) * | 1979-06-28 | 1981-04-28 | Ciba Geigy Ag | STABILIZERS FOR CHLORINATED THERMOPLASTIC COMPOUNDS |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
JPH07116139B2 (en) | 1986-06-09 | 1995-12-13 | 三菱化学株式会社 | Method for producing lactams |
DE3717068A1 (en) * | 1987-05-21 | 1988-12-08 | Basf Ag | 4-SUBSTITUTED 10-CYANMETHYLENE PYRROLO (4,3-E) -BENZO-AZEPINE |
JPH04145078A (en) | 1990-10-04 | 1992-05-19 | Hokko Chem Ind Co Ltd | Pyrroledicarboxylic acid derivative and herbicide |
JPH10251258A (en) * | 1997-03-14 | 1998-09-22 | Suntory Ltd | Pyrroloazepine-based compound |
DE19719585A1 (en) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | New N-sulphonyl-di:amino:carboxylic acid derivatives |
WO1999036068A1 (en) * | 1998-01-14 | 1999-07-22 | Nippon Shinyaku Co., Ltd. | Potassium channel activators |
WO1999050264A1 (en) * | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Quinazoline derivatives |
GB9817548D0 (en) * | 1998-08-12 | 1998-10-07 | Novartis Ag | Organic compounds |
BR9915194A (en) * | 1998-11-09 | 2001-08-07 | Black James Foundation | Compound, method for making the same, pharmaceutical composition, and method for making the same |
ES2234564T3 (en) * | 1999-02-10 | 2005-07-01 | Mitsubishi Pharma Corporation | AMIDA TYPE COMPOUNDS AND THEIR USE IN MEDICINE. |
MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
UA76475C2 (en) | 2001-07-19 | 2006-08-15 | Pharmacia Corp | Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system |
WO2003007955A2 (en) * | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
US6987123B2 (en) * | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
US20070010562A1 (en) | 2001-08-13 | 2007-01-11 | Ulrike Bauer | Nr1h4 nuclear receptor binding compounds |
WO2003015777A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
DE60131967D1 (en) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4 nuclear receptor binding compounds |
DE10148328A1 (en) | 2001-09-29 | 2003-04-10 | Bayerische Motoren Werke Ag | Method for positioning a motor vehicle steering wheel |
US7078430B2 (en) * | 2002-07-08 | 2006-07-18 | Ranbaxy Laboratories Limited | HMG CoA-reductase inhibitors |
MXPA05001688A (en) * | 2002-08-12 | 2005-04-19 | Sugen Inc | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors. |
EP1398029A1 (en) * | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
CN1485072A (en) | 2002-09-28 | 2004-03-31 | 李大鹏 | Coix seed oil soft capsule for curing prostate diseases and the application thereof |
US20040102511A1 (en) | 2002-11-21 | 2004-05-27 | Jitendra Sattigeri | Substituted pyrrole derivatives |
CA2511905A1 (en) * | 2003-01-02 | 2004-07-22 | F. Hoffmann-La Roche Ag | Novel cb 1 receptor inverse agonists |
AU2003298227A1 (en) | 2003-01-02 | 2004-07-29 | F. Hoffmann-La Roche Ag | Novel cb 1 receptour inverse agonists |
JP4703649B2 (en) * | 2004-07-30 | 2011-06-15 | エグゼリクシス, インコーポレイテッド | Pyrrole derivatives as pharmaceutical agents |
-
2005
- 2005-07-30 JP JP2007523832A patent/JP4703649B2/en active Active
- 2005-07-30 SG SG200905207-7A patent/SG155188A1/en unknown
- 2005-07-30 AU AU2005266890A patent/AU2005266890C1/en active Active
- 2005-07-30 HU HUE05803281A patent/HUE041596T2/en unknown
- 2005-07-30 EP EP05803281.4A patent/EP1773768B8/en active Active
- 2005-07-30 KR KR1020077004302A patent/KR101155288B1/en active IP Right Grant
- 2005-07-30 RU RU2007107388/04A patent/RU2470916C2/en active
- 2005-07-30 LT LTEP05803281.4T patent/LT1773768T/en unknown
- 2005-07-30 WO PCT/US2005/026916 patent/WO2006012642A2/en active Application Filing
- 2005-07-30 SI SI200532237T patent/SI1773768T1/en unknown
- 2005-07-30 PL PL05803281T patent/PL1773768T3/en unknown
- 2005-07-30 PT PT05803281T patent/PT1773768T/en unknown
- 2005-07-30 DK DK05803281.4T patent/DK1773768T3/en active
- 2005-07-30 ES ES05803281T patent/ES2697524T3/en active Active
- 2005-07-30 CA CA2573426A patent/CA2573426C/en active Active
- 2005-07-30 BR BRPI0513677A patent/BRPI0513677B8/en active IP Right Grant
- 2005-07-30 US US11/572,962 patent/US8026237B2/en active Active
- 2005-07-30 NZ NZ552632A patent/NZ552632A/en unknown
-
2007
- 2007-01-10 IL IL180630A patent/IL180630A/en active IP Right Grant
- 2007-02-16 NO NO20070910A patent/NO344324B1/en unknown
-
2010
- 2010-01-15 JP JP2010007511A patent/JP2010077166A/en active Granted
-
2011
- 2011-08-22 US US13/214,665 patent/US8367667B2/en active Active
-
2018
- 2018-11-21 CY CY181101235T patent/CY1120922T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040267028A1 (en) * | 2001-09-24 | 2004-12-30 | Smith Roger A | Preparation and use of pyrrole derivatives for treating obesity |
WO2004058249A1 (en) * | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006012642A3 (en) | Pyrrole derivatives as pharmaceutical agents | |
TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
WO2006020680A3 (en) | Heterocyclic compounds as pharmaceutical agents | |
WO2005009387A3 (en) | Azepine derivatives as pharmaceutical agents | |
WO2007109120A3 (en) | Imidazolothiazole compounds for the treatment of disease | |
WO2005069865A3 (en) | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | |
WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
WO2007087068A3 (en) | Inhibitors of tyrosine kinases and uses thereof | |
WO2009055331A3 (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
WO2006086562A3 (en) | Phenylazetidinone derivatives | |
WO2005004808A3 (en) | TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS | |
WO2007092065A3 (en) | Compounds and compositions as lxr modulators | |
WO2007075895A3 (en) | Heterocyclic derivatives as modulators of ion channels | |
WO2005105780A3 (en) | Compositions useful as inhibitors of rock and other protein kinases | |
WO2006116221A3 (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
WO2005103050A3 (en) | Azaindoles useful as inhibitors of rock and other protein kinases | |
WO2007038669A3 (en) | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | |
TW200700406A (en) | Novel thiophene derivatives | |
TW200716591A (en) | Novel thiophene derivatives | |
TW200738670A (en) | Novel thiophene derivatives | |
WO2009071689A3 (en) | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases | |
WO2007050587A3 (en) | Therapeutic compositions and methods | |
EA201001332A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
WO2006047032A3 (en) | Indole compounds useful as serotonin selective agents | |
WO2005077122A3 (en) | Compounds and compositions as lxr modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2573426 Country of ref document: CA Ref document number: 180630 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200700352 Country of ref document: ZA Ref document number: 2005266890 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 552632 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005803281 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 605/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500256 Country of ref document: PH Ref document number: 1200700186 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/001201 Country of ref document: MX Ref document number: 2007523832 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005266890 Country of ref document: AU Date of ref document: 20050730 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580026842.3 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005266890 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077004302 Country of ref document: KR Ref document number: 07018563 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007107388 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005803281 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0513677 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11572962 Country of ref document: US |